WORK Medical Technology Group Ltd.

WORK Medical Technology Group LTD, together with its subsidiaries, manufactures and sells medical consumables in the People's Republic of China and internationally. The company offers disposable medical devices, such as medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half mask; and visualized prostatic dilatation catheters. It also exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.

WORK Medical Technology Group Ltd. trades as WOK on NASDAQ. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $9.85M of revenue and -$1.07M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

WORK Medical Technology Group Ltd. can be compared against peers such as Artelo Biosciences, Inc., bioAffinity Technologies, Inc., Indaptus Therapeutics, Inc., Jasper Therapeutics, Inc., Lipella Pharmaceuticals Inc., Mobile-health Network Solutions Class A Ordinary Shares.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $496, beta of 1.26, and return on equity of -5.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

WOK currently shows total debt of $6.45M and beta of 1.26. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 6-K (2026-06-05 00:00:00), SC 13G (2026-06-04 00:00:00), 3 (2026-06-03 00:00:00), 3 (2026-06-02 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.hzsy120.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.